fr   en
Agreements
Select a partner :
Type of agreement :





Select a compound/Disease :
Choose date:
1   |   2   |   3   |   4   |   5   |   6   |   7   |   8   |   9   |   10   |   11      »      [65]
Date Partners Compound / Disease area / Development phase Type of agreement Nature / Financial terms
2010-09-13 Pharming (The Netherlands)
Santarus (USA)

Rhucin® (recombinant human C1 inhibitor; Ruconest® in Europe)
/ acute angioedema attacks in patients with Hereditary Angioedema (HAE) and other future indications
commercialization/ distribution
See details
2010-09-13 Pharming (The Netherlands)
Santarus (USA)

Rhucin® (recombinant human C1 inhibitor; Ruconest® in Europe)
/ acute angioedema attacks in patients with Hereditary Angioedema (HAE) and other future indications
commercialization/ distribution
See details
2010-09-10 Galapagos (Belgium)
Genentech (USA)

drug discovery programs that utilize Argenta's expertise to discover new chemical entities acting against undisclosed drug targets defined by Genentech.
R&D
other
See details
2010-09-09 Atheris Laboratories (Switzerland)
Bachem (Switzerland)
Melusine® libraries (natural products isolated from animal venoms, mainly peptide toxins)
R&D
development
other
See details
2010-09-09 Shire Pharmaceuticals (UK)
Acceleron Pharma (USA)

activin receptor type IIB (ActRIIB) class of molecules including ACE-031 / Duchenne Muscular Dystrophy
R&D
licensing
commercialization/ distribution
development
See details
2010-09-08 Galapagos (Belgium)

GSK (UK)
GSK research centre in Zagreb
This center was GSK's Macrolide Center of Excellence for Drug Discovery
R&D
other
See details
2010-09-08 Lonza (Switzerland)

GSK (UK)
Five monoclonal antibodies / undisclosed manufacturing
See details
2010-09-07 reMYND (Belgium)

Roche (Switzerland)
small molecule programmes targeting á-synuclein and tau related pathologies / Parkinson’s disease, Alzheimer’s disease and other neurodegenerative disorders
R&D
licensing
commercialization/ distribution
development
See details
2010-09-06 Stallergènes (France)

Shionogi (Japan)
Actair® house dust mite tablets and Japanese cedar pollen tablets
These two immunotherapy tablets are included in Stalair®, the pharmaceutical and clinical development program for immunotherapy tablets being implemented by Stallergenes with a view to obtaining marketing authorizations for pharmaceutical products in Europe and in other strategic markets.
The three other development programs are Oralair® (grass pollen), r Bet v 1 (birch pollen recombinant allergen), and ragweed pollen. / allergy
commercialization/ distribution
development
marketing/ promotion
See details
2010-09-03 Ipsen (France)
Santhera Pharmaceuticals (Switzerland)
Fipamezole (antagonist of the adrenergic alpha-2 receptor) / levodopa-induced dyskinesia in Parkinson’s Disease
commercialization/ distribution
development
See details
2010-09-02 Morphosys (Germany)
Absynth (UK)

novel infectious disease targets / Staphylococcus aureus infections including MRSA (methicillin-resistant S. aureus). R&D
licensing
other
See details
2010-08-31 BTG (UK)

Nycomed USA
Antivenom serum CroFab®(Crotalidae Polyvalent Immune Fab)
Antidigoxin antibody DigiFab® (Digoxin Immune Fab)
/ digoxin toxicity or overdose
commercialization/ distribution
marketing/ promotion
See details
2010-08-30 Kythera Biopharmaceuticals (USA)

Intendis (Bayer HealthCare’s Dermatology Unit - Germany)
ATX-101
This adipolytic agent is based on an undisclosed well-studied endogenous molecule with unique features including selectivity for adipocytes and rapid clearance. It has been designed to reduce small volumes of facial fat through aesthetics’ applications first-in-class injectable drug being studied for the reduction of small volumes of fat, including submental fat. / reduction of small localized volumes of fat, including submental fat (under the chin).
licensing
See details
2010-08-27 Basilea Pharmaceutica (Switzerland)
Actelion (Switzerland)

Toctino® (alitretinoin)
/ severe chronic hand eczema unresponsive to potent topical corticosteroids
commercialization/ distribution
See details
2010-08-25 TiGenix (Belgium)
Catholic University Leuven (Belgium)
Ghent University (Belgium)
Therosteon (The Netherlands)
consortium of investors

disease modifying drugs
/ bone and joint diseases
other
See details
1   |   2   |   3   |   4   |   5   |   6   |   7   |   8   |   9   |   10   |   11      »      [65]